Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.